Revolutionising healthcare worldwide through continuously improving diagnostic solutions

1. Revolutionising healthcare worldwide through continuously improving diagnostic solutions Dr Ciaran Richardson Med Tech H2020 Conference 18th Sept 2013

2. Privately owned diagnostic and instrument company • UK and Ireland’s largest indigenous diagnostic company • Established in 1982 • Employs over 1,200 people, including 300 scientists and engineers

3. 20th position out of an estimated 1,850 diagnostic companies worldwide • 6th largest manufacturer of clinical chemistry reagents in the world • Randox manufactures 11% of all HDL Cholesterol tests used worldwide • 4th in supply of QC serum and calibrators • Number 1 in supply to international EQA schemes

4. PRODUCT PORTFOLIO

5. Randox Sales Conference October 2008 Biochip Array Technology Simultaneous detection of multiple analytes from a single undivided patient sample • Based on sound ELISA principles • Over 185 scientists and engineers developed the technology • £120 million investment • Forefront of in vitro diagnostics

6. Biochip Array Technology Huge versatility of technology Expanding portfolio Excellent QC throughout

8. Research and Development Facilities 260,000 sq ft facility Antrim, Northern Ireland 70,000 sq ft facility Donegal, Republic of Ireland

9. Highly innovative… . . with over 400 new tests in development Randox Sales Conference October 2008

10. Randox Collaborations • Randox has >40 research collaborations with Universities and other businesses to: • Discover novel biomarkers of disease • Develop new diagnostic assays • Identify novel multiplex arrays for clinical use • Clinically validate new diagnostic tests and multiplex arrays • Develop improved technologies

11. Lipid Profile Genetic Predisposition Hypertension Heart Failure Panel Stroke Biomarker Familial Hypercholesterolaemia (FH) Cardiovascular Disease Metabolic Syndrome Profile Cardiac Markers (H-FABP) Aspirin Resistance (TxB Cardio) Clopidogrel Warfarin Metabolism Genetic Predisposition (CAD) COLLABORATION

12. Randox are actively participating in FP7 funded projects: EU-MASCARA, Cardiovascular disease biomarkers http://www.eu-mascara.eu/ EuroHYP-1, Stroke biomarkers http://www.eurohyp1.eu/ EU-Homage, Heart Failure biomarkers http://www.homage-hf.eu/ Company has expanded rapidly in recent years Increased R&D investment will further accelerate rate of expansion and rate of job creation 25% of all positions in R&D Seventh Framework Proramme (FP7)

13. Randox aim to have greater participation in H2020 compared to FP7 R&D facilities are located in the Republic of Ireland and Northern Ireland Actively participate in project conceptualisation with key strategic partners Invaluable opportunity to collaborate with specialist personnel from both industry and academia Opportunity to accelerate R&D aspirations by participating in funded collaborative projects Promote further company expansion and job creation Actively seeking relevant project partners in advance of H2020 funding calls Horizon 2020 (H2020)

14. Health Materials Information and Communications Technology Research and Development Biotechnology Diagnostics Nanotechnology H2020 PARTNERS

15. Revolutionising healthcare worldwide through continuously improving diagnostic solutions